Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.
作者信息
Tchirkov A, Couderc J-L, Périssel B, Goumy C, Regnier A, Uhrhammer N, Verrelle P, Berger M
出版信息
Leukemia. 2006 Jan;20(1):167-8. doi: 10.1038/sj.leu.2404012.
Abstract
摘要
相似文献
1
Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.
Leukemia. 2006 Jan;20(1):167-8. doi: 10.1038/sj.leu.2404012.
2
CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.
Leuk Res. 2005 Nov;29(11):1365-6. doi: 10.1016/j.leukres.2005.04.001.
3
Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
Pediatr Blood Cancer. 2008 May;50(5):1078. doi: 10.1002/pbc.21439.
4
5
Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Cancer Genet Cytogenet. 2007 Apr 15;174(2):111-5. doi: 10.1016/j.cancergencyto.2006.11.021.
6
Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Leuk Res. 2013 Sep;37(9):1035-40. doi: 10.1016/j.leukres.2013.06.003. Epub 2013 Jun 26.
7
Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Acta Haematol. 2008;120(3):146-9. doi: 10.1159/000178145. Epub 2008 Nov 28.
8
Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib.
Leukemia. 2005 Dec;19(12):2334-6. doi: 10.1038/sj.leu.2403986.
9
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Leukemia. 2003 Sep;17(9):1687-94. doi: 10.1038/sj.leu.2403033.
10
Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response.
Ann Hematol. 2003 Jun;82(6):333-5. doi: 10.1007/s00277-003-0660-y. Epub 2003 May 7.
引用本文的文献
1
A case report of pediatric acute lymphoblastic leukemia with e8a2 BCR/ABL1 fusion transcript.
BMC Med Genomics. 2022 Feb 5;15(1):20. doi: 10.1186/s12920-022-01169-0.
2
A Novel e8a2BCR-ABL1 Fusion Transcript without Insertion Sequence in a Patient with Chronic Myeloid Leukemia.
Ann Lab Med. 2018 Mar;38(2):169-171. doi: 10.3343/alm.2018.38.2.169.
3
Novel BCR-ABL1 fusion and leukemic mutations of SETBP1, PAX5, and TP53 detected by next generation sequencing in chronic myeloid leukemia.
Cancer Biol Ther. 2016 Oct 2;17(10):1003-1009. doi: 10.1080/15384047.2016.1219821. Epub 2016 Sep 10.
4
A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia.
Mol Cytogenet. 2016 Jun 27;9:47. doi: 10.1186/s13039-016-0257-5. eCollection 2016.
5
Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemia.
J Mol Diagn. 2010 Jul;12(4):520-4. doi: 10.2353/jmoldx.2010.090218. Epub 2010 May 27.
本文引用的文献
1
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Clin Cancer Res. 2005 May 1;11(9):3425-32. doi: 10.1158/1078-0432.CCR-04-2139.
2
e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants?
Leukemia. 2005 Apr;19(4):681-4. doi: 10.1038/sj.leu.2403604.
3
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
Leukemia. 2003 Dec;17(12):2318-57. doi: 10.1038/sj.leu.2403135.
4
5
P190 BCR/ABL transcript in a case of Philadelphia-positive multiple myeloma.
Leukemia. 1990 Nov;4(11):751-4.
Zotero 插件